Innate Pharma SA has obtained IND clearance from the FDA for IPH-4502, its novel and differentiated topoisomerase I inhibitor antibody-drug conjugate (ADC) conjugated to exatecan targeting Nectin-4 in solid tumors. In nonclinical models, IPH-45 was well tolerated and showed antitumor efficacy in vitro and in vivo.
Chengdian (Suzhou) Biopharmaceutical Co. Ltd. has received IND clearance from the FDA, allowing it to initiate a first-in-human phase I trial of CD-001.
CDR-Life Inc. has reported preclinical data for the CDR-813, a novel antibody fragment-based bivalent T-cell engager targeting preferentially expressed antigen in melanoma (PRAME) on HLA-A*02:01.
Rakuten Medical Inc. has presented preclinical results with RM-0256, a PD-L1-targeted photoimmunotherapy, showing its ability to kill immunosuppressive myeloid cells to activate local and systemic antitumor immunity.
Guangdong HEC Pharmaceutical Co. Ltd. has described programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) interaction inhibitors reported to be useful for the treatment of cancer, infections and autoimmune disease.
OS Therapies Inc. has announced the development and in vitro concept data for two novel tunable antibody-drug conjugate (tADC) therapeutic candidates leveraging the company’s proprietary Silinker technology.
UL16 binding protein 6 (ULBP6) is a molecule belonging to the stress-induced NKG2D ligand family and its expression is up-regulated on the surface of cancerous cells, binding to the immune-activating NKG2D receptor on natural killer (NK) and T cells, thus promoting immune evasion.
Metastatic solid tumors may be curable now. Among the most profound results presented over the weekend at the European Society for Medical Oncology (ESMO) 2024 Congress were the 10-year data from the Checkmate-067 and Keynote-006 trials, the phase III trials that tested Opdivo (nivolumab, Bristol Myers Squibb Co.) and Keytruda (pembrolizumab, Merck & Co. Inc.) as first-line agents in advanced or metastatic melanoma.
Vironexis Biotherapeutics Inc. has come out of stealth mode, disclosing that it has more than 10 product candidates it’s been developing over the last three years. The therapies are built on the company’s AAV-based platform, Transjoin, which is designed to have patients' livers express bispecific antibodies that bind to both CD3 on T-cells and various targets on tumor cells.
RSS
